ESC 365 - Impact of early initiation of SGLT2 inhibitor on cardiovascular outcomes in diabetic patients with known atherosclerotic cardiovascular disease or risk factors: propensity score matched analysis

ESC Premium Access

Impact of early initiation of SGLT2 inhibitor on cardiovascular outcomes in diabetic patients with known atherosclerotic cardiovascular disease or risk factors: propensity score matched analysis

Session: Can we improve outcomes by targeting metabolic risk?

Topic: Pharmacotherapy

Speaker: Doctor W. Sun (Shatin, HK)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Doctor Wen Sun

Prince of Wales University Hospital, Shatin (Hong Kong)

0 follower

4 more presentations in this session

Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies.

Speaker: Professor M. Banach (Lodz, PL)

Mediation analyses of the effect of ertugliflozin on hospitalisation for heart failure in patients with type 2 diabetes and atherosclerotic cardiovascular disease from the VERTIS CV trial

Speaker: Doctor M. Segar (Houston, US)

Changes in EPA and DHA during supplementation with Omega-3 fatty acids and incident cardiovascular events: secondary analysis from the OMEMI trial

Speaker: Doctor P. Myhre (Akershus, NO)

Cardiorenal outcomes with ertugliflozin by baseline metformin use: post-hoc analyses of the VERTIS CV trial

Speaker: Doctor F. Cosentino (Stockholm, SE)

Access the full session

Can we improve outcomes by targeting metabolic risk?

Speakers: Doctor W. Sun, Professor M. Banach, Doctor M. Segar, Doctor P. Myhre, Doctor F. Cosentino

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Related content

ESC Premium Access

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

ESC 365 is supported by